CD274 and non-small cell lung carcinoma: Therefore, each PD-1/PD-L1 inhibitor has a different companion or complementary diagnostic: Dako 28-8 with nivolumab (Bristol-Myers Squibb, Princeton, NJ, USA), Dako 22C3 with pembrolizumab (Merck & Co., Inc. Rahway, NJ, USA), Ventana SP263 with durvalumab (AstraZeneca, Cambridge, UK), and Ventana SP142 with atezolizumab (Roche, Basel, Switzerland) in locally advanced, and advanced NSCLC [11].